my personal edition > rheumatology other > news
E-Mail this DGNews to a colleague
DGNews
No Evidence that COX-2 inhibitors Provide Greater Stomach Protection
LONDON, UK -- December 2, 2005 -- There is no evidence to back up claims that the new generation of anti-inflammatory drugs (COX-2 inhibitors) are less harmful to the stomach lining than many traditional anti-inflammatory drugs, concludes a study in this week's BMJ.
These drugs were specifically designed to provide pain relief without the serious gastrointestinal side effects associated with the traditional non-steroidal anti-inflammatory drugs.
Researchers at the University of Nottingham identified patients from 367 UK general practices with a first ever diagnosis of an upper gastrointestinal event (stomach ulcer or bleed). Each case was matched with up to 10 control patients.
Prescriptions for anti-inflammatory drugs and aspirin issued in the 3 years before the study were identified for both cases and controls.
Of 9407 cases, 45% had been prescribed a conventional non-steroidal anti-inflammatory drug (NSAID) in the previous three years and 10% had been prescribed a COX-2 inhibitor. Of 88,867 controls, 33% had been prescribed an NSAID and 6% had been prescribed a COX-2 inhibitor.
Increased risks of adverse gastrointestinal events were associated with current use of COX-2 inhibitors and with conventional non-steroidal anti-inflammatory drugs. Risks were reduced after adjusting for other factors, but remained significantly increased for naproxen, diclofenac, and rofecoxib, but not for current use of celecoxib.
The use of ulcer healing drugs reduced the risk with all groups of non-steroidal anti-inflammatory drugs, although for diclofenac the increased risk remained significant.
Evidence of enhanced gastrointestinal safety with any of the new cyclo-oxygenase-2 inhibitors compared with non-selective non-steroidal anti-inflammatory drugs is lacking, say the authors.
These results suggest that COX-2 inhibitors may not be as safe as originally thought, although a possible confounding effect cannot be ruled out, they conclude.
REFERENCE:
Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; Volume 331, pp 1310-12.
SOURCE: British Medical Journal
All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.
| 
